Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction

Oral Oncology

Volumn 44, Issue 2, 2008, Pages 162-173

  Jensen, Siri Beier ^a   Mouridsen, Henning T ^b   Reibel, Jesper ^a   Brünner, Nils ^c   Nauntofte, Birgitte ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adjuvant chemotherapy; Breast cancer; Hyposalivation; Salivary glands; Xerostomia

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HYPOSALIVATION; LEUKOCYTE; LEUKOPENIA; NAUSEA AND VOMITING; PAROTID ENLARGEMENT; PAROTID GLAND; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SALIVA; SALIVARY GLAND FUNCTION; SUBMANDIBULAR GLAND; THROMBOCYTE; THROMBOCYTOPENIA; XEROSTOMIA;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; ELECTROLYTES; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN A, SECRETORY; MIDDLE AGED; SALIVA; SALIVARY GLANDS; SALIVARY PROTEINS; SALIVATION; SECRETORY RATE; XEROSTOMIA;

EID: 38849184685     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.01.015     Document Type: Article

References (39)

1. de Jonge M.E., Huitema A.D., Rodenhuis S., and Beijnen J.H. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44 (2005) 1135-1164
2. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 54 Suppl. 4 (1997) 1-7
3. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M., Hauer-Jensen M., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 (2004) 1995-2025
4. Jensen S.B., Pedersen A.M., Reibel J., and Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11 (2003) 207-225
5. Hofer E., Jensen S.B., Pedersen A.M.L., Bardow A., and Nauntofte B. Oral microflora in patients with salivary gland hypofunction. Oral Biosci Med 1 (2004) 93-108
6. Epstein J.B., Tsang A.H., Warkentin D., and Ship J.A. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 (2002) 39-44
7. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
8. Plosker G.L., and Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45 (1993) 788-856
9. Bleyer W.A. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41 (1978) 36-51
10. Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park) 12 (1998) 19-22
11. Pedersen A.M., Bardow A., Jensen S.B., and Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis 8 (2002) 117-129
12. Bergmann O.J. Humoral immunity of the oral cavity during remission-induction therapy in patients with acute myeloid leukaemia. Eur J Haematol 44 (1990) 296-301
13. Wahlin Y.B. Salivary secretion rate, yeast cells, and oral candidiasis in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 71 (1991) 689-695
14. Main B.E., Calman K.C., Ferguson M.M., Kaye S.B., MacFarlane T.W., Mairs R.J., et al. The effect of cytotoxic therapy on saliva and oral flora. Oral Surg Oral Med Oral Pathol 58 (1984) 545-548
15. Ohrn K.E., Wahlin Y.B., and Sjoden P.O. Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer 9 (2001) 247-257
16. Meurman J.H., Laine P., Keinanen S., Pyrhonen S., Teerenhovi L., and Lindqvist C. Five-year follow-up of saliva in patients treated for lymphomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83 (1997) 447-452
17. Sreebny L.M., and Schwartz S.S. A reference guide to drugs and dry mouth - 2nd edition. Gerodontology 14 (1997) 33-47
18. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334 (1987) 1-100
19. Fox P.C., Busch K.A., and Baum B.J. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 115 (1987) 581-584
20. Navazesh M., and Christensen C.M. A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 61 (1982) 1158-1162
21. 2. Arch Oral Biol 45 (2000) 1-12
22. Fried R., Hoeflmayr J., and Velosy G. [A new, highly sensitive method for the determination of chloride in body fluids without protein precipitation (author's transl)]. Z Klin Chem Klin Biochem 10 (1972) 280
23. Goldenberg H., and Fernandez A. Simplified method for the estimation of inorganic phosphorus in body fluids. Clin Chem 12 (1966) 871-882
24. Bardow A., Madsen J., and Nauntofte B. The bicarbonate concentration in human saliva does not exceed the plasma level under normal physiological conditions. Clin Oral Investig 4 (2000) 245-253
25. Sreebny L.M., and Valdini A. Xerostomia. Part I: Relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66 (1988) 451-458
26. Sreebny L.M. Saliva in health and disease: an appraisal and update. Int Dent J 50 (2000) 140-161
27. Thaysen J.H., Thorn N.A., and Schwartz I.L. Excretion of sodium, potassium, chloride and carbon dioxide in human parotid saliva. Am J Physiol 178 (1954) 155-159
28. Harrison T., Bigler L., Tucci M., Pratt L., Malamud F., Thigpen J.T., et al. Salivary sIgA concentrations and stimulated whole saliva flow rates among women undergoing chemotherapy for breast cancer: an exploratory study. Spec Care Dentist 18 (1998) 109-112
29. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 66 Spec No (1987) 648-653
30. Lockhart P.B., and Sonis S.T. Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study. J Dermatol Surg Oncol 7 (1981) 1019-1025
31. Romaniuk K, Gavin JB, Adkins KF. The effect of methotrexate on salivary glands in the rat. Abstract number 261,1983 ed. 1983:678.
32. Wolff A., Moreira J.E., Marmary Y., and Fox P.C. Lack of acute effects of methotrexate on rat parotid salivary gland function. Arch Oral Biol 34 (1989) 109-115
33. Blomgren J., Jansson S., Rodjer S., and Birkhed D. Secretion rate from minor salivary glands in patients with malignant haematological diseases receiving chemotherapy-a pilot study. Swed Dent J 26 (2002) 75-80
34. McBride R.K., Harper C., and Siegel I.A. Methotrexate-induced changes in rat parotid and submandibular gland function. J Dent Res 66 (1987) 1445-1448
35. Izutsu K.T., Truelove E.L., Bleyer W.A., Anderson W.M., Schubert M.M., and Rice J.C. Whole saliva albumin as an indicator of stomatitis in cancer therapy patients. Cancer 48 (1981) 1450-1454
36. Laine P., Meurman J.H., Tenovuo J., Murtomaa H., Lindqvist C., Pyrhonen S., et al. Salivary flow and composition in lymphoma patients before, during and after treatment with cytostatic drugs. Eur J Cancer B Oral Oncol 28B (1992) 125-128
37. Pajari U., Poikonen K., Larmas M., and Lanning M. Salivary immunoglobulins, lysozyme, pH, and microbial counts in children receiving anti-neoplastic therapy. Scand J Dent Res 97 (1989) 171-177
38. Miksicek R.J., Myal Y., Watson P.H., Walker C., Murphy L.C., and Leygue E. Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Res 62 (2002) 2736-2740
39. Meurman J.H., Laine P., Lindqvist C., Pyrhonen S., and Teerenhovi L. Effect of anticancer drugs on patients with and without initially reduced saliva flow. Eur J Cancer B Oral Oncol 30B (1994) 204-208